

## News Alert

January 5, 2023

### **Zai Lab's share price is up 40% after positive phase 3 results in lung cancer**

Today, portfolio company Zai Lab and its partner Novocure announced that the phase 3 study investigating their new therapy for late-stage lung cancer patients resulted in improved overall survival. The same therapy, called Tumor Treating Fields, is already approved and used to treat a rare aggressive form of brain cancer (glioblastoma multiforme) and to treat a specific form of lung cancer, called pleural mesothelioma.

Zai Lab signed the deal with Novocure to commercialize the tumor treatment fields in China, Hong Kong, Macau and Taiwan back in 2018, and has been providing this much-needed treatment in those regions ever since. Although the types of cancers treated with this therapy so far are relatively rare, limiting market size, lung cancer is the 2nd most common cancer in the world, and the most common cancer in China.

This means now many more patients can benefit from this innovative treatment and the commercial opportunity has increased significantly. We expect this to be an important value driver for Zai Lab in the future. Zai Lab's share price today is rising 40% on the news.

We look forward to announce further news from Zai Lab in 2023.

Best regards on behalf of the Aescap team,

Patrick J. H. Krol  
*Portfolio Manager Aescap*